Abstract: A process for the production of a fluorinated quartz glass including the steps of generating SiO2 particles in a synthesis burner; depositing the resulting SiO2 particles into a body; and vitrifying the resulting body, wherein a fluorinating agent having a boiling point greater than or equal to ?10° C. is supplied to the synthesis burner.

Abstract: A semiconductor wafer imaging system for imaging a semiconductor wafer includes shroud panels defining a black box, a camera positioned in the black box for imaging the semiconductor wafer, and an illumination panel for directing diffuse light to the semiconductor wafer. A portion of the diffuse light is reflected off the semiconductor wafer and the camera images the semiconductor wafer by detecting the reflected diffuse light.

Abstract: Systems, methods, and computer program products for easily altering redundancy management data values associated with redundancy management logic that is executed by redundant data processing systems. The redundancy management data values are altered on a computer device remote from the system that includes the redundant data processing systems.

Abstract: Circulation-active dihydropyridines of the formula ##STR1## in which R.sup.1 is H, CN, NO.sub.2 or --COOR.sup.7,R.sup.7 is H, alkyl or various other radicals,R.sup.2 and R.sup.4 each independently is alkyl or other radicals,R.sup.3 is H or optionally substituted alkyl, andR.sup.5 completes a keto or ester group,and physiologically acceptable salts thereof.

Abstract: 4 Aminoaryldihydropyridines of the formula ##STR1## in which R.sup.1 is hydrogen or an organic radical, preferably methyl or ethyl,R.sup.2 is hydrogen, C.sub.1 -C.sub.5 - alkyl, --CN, --NH.sub.2, --CH.sub.2 or --CH.sub.2 OH, preferably methyl,R.sup.3 is hydrogen or alkyl, preferably hydrogen,Y is --CO-- or --SO.sub.2 --, andR.sup.4 is an organic radical, orY-R.sup.4 is hydrogen,and physiologically acceptable salts thereof, are circulation-active and effective for improving myocardial contractility, for raising blood pressure, for lowering blood sugar, for reducing mucosal swelling and for controlling the salt and fluid balance.

Abstract: Circulation-active fluoromethoxyphenyldihydropyridines of the formula ##STR1## in which X stands for hydrogen or fluorine andR stands for straight-chain, branched or cyclic alkyl or alkenyl having 2 to 12 carbon atoms which can be interrupted by 1 to 2 oxygen and/or sulphur atoms in the chain, and which can be monosubstituted or polysubstituted(a) by hydroxyl, aryl having 6 to 12 carbon atoms, aryloxy having 6 to 12 carbon atoms, where the aryl radical is again substituted by alkyl having up to 4 carbon atoms, alkoxy having up to 4 carbon atoms or halogen, the substituents being identical or different, or(b) by carboxyl, alkoxycarbonyl having up to 6 carbon atoms, pyridyl, piperidyl, pyrimidyl, acyloxy having up to 7 carbon atoms, sulphamoyl, carbamoyl, halogen or cyano, the substituents being identical or different, or(c) by an amino group, where the amino group can carry one or two identical or different substituents from the group consisting of alkyl having up to 6 carbon atoms, benzyl, phenyl or acyl havi

Abstract: A benzylaminoaryl-dihydropyridinelactone compound of the formula (I) ##STR1## in which R.sup.1 represents hydrogen, halogen, cyano, nitro, C.sub.6 -C.sub.12 -aryl, C.sub.1 -C.sub.8 -alkyl, C.sub.1 -C.sub.8 -alkoxy, C.sub.1 -C.sub.6 -alkylthio, trifluoromethyl, trifluoromethoxy, trifluoromethylthio, difluoromethoxy, di-C.sub.1 -C.sub.5 -alkylamino, C.sub.1 -C.sub.6 -alkoxycarboxyl or C.sub.1 -C.sub.6 -alkylsulphonyl,R.sup.2 represents hydrogen, or represents a straight-chain, branched or cyclic, saturated or unsaturated hydrocarbon radical having up to 10 carbon atoms which is optionally substituted by C.sub.1 -C.sub.6 -alkoxy, C.sub.1 -C.sub.6 -alkylthio, C.sub.1 -C.sub.6 -alkylsulphonyl, halogen, cyano, hydroxyl, pyridyl, thienyl, pyrimidyl, piperidinyl, phenyl or an amino group, where the amino group carries two identical or different substituents from the series comprising C.sub.1 -C.sub.5 -alkyl, phenyl or benzyl,R.sup.3 represents C.sub.1 -C.sub.

Abstract: Novel circulation-active cyclohexenecarboxylates of the formula ##STR1## in which R.sup.1 is an organic radical,R.sup.2 is an optionally substituted aryl radical,R.sup.3 is an optionally substituted alkyl or aryl radical,X and Y are --CN, --COR.sup.4, --SO.sub.2 R.sup.4, --COOR.sup.5, --CONR.sup.6 R.sup.7 or --SO.sub.2 NR.sup.6 R.sup.7, andR.sup.4, R.sup.5, R.sup.6 and R.sup.7 are various organic radicals.

Abstract: Circulation active nitrodihydropyridines of the formula ##STR1## in which R represents aryl which has 6 to 12 carbon atoms and can be substituted up to 4 times, identically or differently, by halogen, nitro, cyano, alkyl, alkoxy, alkylthio, in each case having up to 6 carbon atoms, trifluoromethyl, trifluoromethoxy, difluoromethoxy, trifluoromethylthio, difluoromethylenedioxy, trifluoroethylenedioxy or tetrafluoroethylenedioxy or by benzyl, benzyloxy or benzylthio, each of which is optionally substituted by halogen, nitro, cyano, trifuoromethyl, alkyl having up to 4 carbon atoms or alkoxy having up to 4 carbon atoms, or represents a heterocycle which is optionally substituted by halogen, phenyl or alkyl having up to 4 carbon atoms and is from the group consisting of pyrryl, thienyl, furyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, pyridyl, pyrimidyl, pyridazinyl, quinolyl, benzoxadiazolyl, chromenyl or thiochromenyl, andn represents a number from 1 to 12,and physiologically acceptable salts thereof.

Abstract: Circulation-active dihydropyridines of the formula ##STR1## in which R.sup.1 is H, CN, NO.sub.2 or --COOR.sup.7,R.sup.7 is H, alkyl or various other radicals,R.sup.2 and R.sup.4 each independently is alkyl or other radicals,R.sup.3 is H or optionally substituted alkyl,R.sup.5 completes a keto or ester group, andR.sup.6 is a direct bond or --CF.sub.2 -- or --CHF--,and physiologically acceptable salts thereof.

Abstract: For the control of coronary diseases and thromboses there are provided the novel compounds ##STR1## in which R.sup.1 is an optionally substituted phenyl or heterocyclic radical,R.sup.2 is a cyano, keto, carboxy, ester or amide group, andX is from 0 to 6,and physiologically acceptable salts thereof.

Abstract: For the treatment of circulation disorders, the novel 5-nitro-1,4-dihydropyridines of the formula ##STR1## in which R represents C.sub.6 -C.sub.14 -aryl which can be mono- to pentasubstituted by identical or different substituents from the series comprising halogen, nitro, cyano, C.sub.1 -C.sub.6 -alkyl, C.sub.1 -C.sub.6 -alkoxy, C.sub.1 -C.sub.6 -alkoxy, C.sub.1 -C.sub.6 -alkylthio, trifluoromethyl, trifluoromethoxy, difluoromethoxy, trifluoromethylthio and benzyl, benzyloxy or benzylthio optionally substituted by nitro, cyano, trifluoromethyl, C.sub.1 -C.sub.4 -alkyl or C.sub.1 -C.sub.4 -alkoxy, orrepresents a heterocycle from the series pyrryl, thienyl, furyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, pyridyl, pyridazinyl, pyrimidyl, quinolyl, benzoxadiazolyl, chromenyl or thiochromenyl optionally mono- to tetrasubstituted by halogen, phenyl or C.sub.1 -C.sub.4 -alkyl orrepresents straight-chain, branched or cyclic alkyl with up to 14 carbon atoms,and their physiologically acceptable salts.

Abstract: Circulation active, e.g. antihypertensive novel methionine-substituted dihydropyridines of the formula ##STR1## in which R.sup.1 is phenyl or a heterocyclic radical, or a physiologically acceptable salt thereof.

Abstract: 4 Aminoaryldihydropyridines of the formula ##STR1## in which R.sup.1 is hydrogen or an organic radical, preferably methyl or ethyl,R.sup.2 is hydrogen, C.sub.1 -C.sub.5 -alkyl, --CN, --NH.sub.2, --CH.sub.2 or --CH.sub.2 OH, preferably methyl,R.sup.3 is hydrogen or alkyl, preferably hydrogen,Y is --CO-- or --SO.sub.2 --, andR.sup.4 is an organic radical, orY--R.sup.4 is hydrogen,and physiologically acceptable salts thereof, are circulation-active and effective for improving myocardial contractility, for raising blood pressure, for lowering blood sugar, for reducing mucosal swelling and for controlling the salt and fluid balance.

Abstract: 5-Aryl-1,4-dihydropyridines of the formula ##STR1## in which Rrepresents cycloalkyl,heteroaryl oraryl which is optionally substituted by at least one substituent independently selected from the group consisting of halogen, nitro, hydroxyl, amino, carboxyl, alkoxycarbonyl, cyano, acyl, acyloxy, acylthio, by alkyl, alkyloxy, alkylthio or alkylsulphonyl, each of which is optionally substituted by one or more halogens, by aryl which is optionally substituted by alkyl, alkoxy, halogen or nitro, or optionally by the group --Z--CH.sub.2 --R.sup.4,whereZ represents oxygen or sulphur, andR.sup.4represents cycloalkyl,heteroaryl oraryl which is optionally substituted by halogen, cyano, nitro, hydroxyl, carboxyl, alkoxycarbonyl or by alkyl or alkoxy, each of which is optionally substituted by one or more halogens,R.sup.1 and R.sup.2are identical or different andrepresent straight-chain or branched alkyl which is optionally substituted by aryl, carboxyl, alkoxycarbonyl or by hydroxyl,R.sup.

Abstract: Novel cardioactive compounds of the formula ##STR1## in which R.sup.1 is alkyl, aryl or heterocyclic, preferably substituted phenyl,R.sup.2 is alkyl, preferably methyl,R.sup.3 is hydrogen, halogen, acyloxy or alkyl, preferably hydrogen, andR.sup.4 is phenyl, carbalkoxy or together with R.sup.3 forms a ring, preferably carbalkoxy,are produced by reducing the corresponding nitro compounds.

Abstract: Circulation-active dihydropyridines of the formula ##STR1## in which R.sup.1 is optionally substituted aryl or heterocyclic,R.sup.2 is H, NO.sub.2, CN, C.sub.1 -C.sub.8 -alkylsulphonyl, aryl or carboalkoxy,R.sup.3 is alkyl or aryl,R.sup.4 is H or alkyl,X is C.dbd.O or a direct bond, andn is a number from 1 to 20,or physiologically acceptable salts thereof. A synthesis using morpholines or thiomorpholines is also disclosed.

Abstract: 1,4-Dihydropyridine-3-carboxylic acid piperazides of the formula ##STR1## in which R.sup.1 is CN or alkyl, preferably methyl,R.sup.2 is H, CN, NO.sub.2 or preferably carboxyalkyl,R.sup.3 is aryl or heterocyclic, andR.sup.4 is alkyl, cycloalkyl, aryl or an acyl radical,and physiologically acceptable salts thereof, are circulation active. Novel intermediates are also provided.

Abstract: Novel compounds of the formula ##STR1## in which R.sup.2 is hydrogen or a substituent, andR.sup.1 is optionally substituted alkyl or alkenyl,exhibit positive inotropic activity on the cardiac muscle, intensifying the contraction power.

Abstract: 1,4-Dihyropyridinecarboxamides of the formula ##STR1## and salts thereof, are effective for treating cardiac insufficiency, thromboses, thromboembolisms and ischaemias, for influencing the blood-sugar level and the circulation and as coronary therapeutic agents and anti-arrhythmic agents.